MIGS Reinvented: eyeFlow featured in Glaucoma Today

eyeFlow, Inc. is developing a highly effective micro-invasive device for the treatment of the world’s largest cause of irreversible blindness that is:

Dual-Action Innovation

eyeFlow replaces Glaucoma drop medication therapy through mechanical stenting paired with sustained, localized drug delivery.

Straightforward

eyeFlow takes Micro Invasive Glaucoma Surgery to the next level with the most accessible, intuitive procedure to date

High Growth Market

eyeFlow is the “Best In Class” of Micro Invasive Glaucoma Surgery which dominates the $5.7 billion Glaucoma treatment market

High Growth Market

eyeFlow is the “Best In Class” of Micro Invasive Glaucoma Surgery which dominates the $5.7 billion Glaucoma treatment market

eyeFlow’s Micro Invasive Glaucoma Surgery (MIGS) device has been evaluated in human clinical studies across multiple international sites, demonstrating sustained IOP reduction and a favorable safety profile through 12+ months of follow-up.

“My early implant experience with eyeflow has been outstanding. I believe its unique design and delivery system is going to appeal to a wide range of physicians and patients as it offers the most consistent mode of implantation.”

Arsham Sheybani, MD

Key Opinion Leader – Micro Invasive Glaucoma Surgery

Join us in Preserving Vision

Explore how investing in eyeFlow can help prevent blindness for millions through groundbreaking technology, while offering unique investment opportunities.
Contact Form Demo

your message will be received by info@eyeflow-inc.com

The eyeFlow microstent is an investigational device and is not yet approved by the FDA. Its safety and effectiveness have not been established in the United States.

© 2026 eyeFlow All rights reserved.